Dolutegravir Archives

25 July 2017

BLOG: We want dolutegravir for all, and we want it now

Advocacy, AIDS, ARV, Dolutegravir, Guidelines, HIV, Middle East, North Africa 99 Views

Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on

21 July 2017

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV …

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Middle East, Morocco, North Africa 79 Views

Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage

20 July 2017

New WHO Guidance Report- Treatment Failure and Drug Resistance

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Pathology, The Global Fund 80 Views

WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA – WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted

23 January 2017

Amendment of the TRIPS Agreement

Advocacy, ARV, Daclatasvir, Dolutegravir, HCV, Health Financing, Hepatitis, HIV, Intellectual Proprety, Pathology, Sofosbuvir, TB 80 Views

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally

2 January 2016

African Treatment Advocates Call on ViiV Healthcare to Unlock Access to Dolutegravir …

Algeria, Dolutegravir, HIV, Intellectual Proprety, Libya, Morocco, REGION, Tunisia 75 Views

Harare, December 1st, 2015 Today, at the International Conference on AIDS and STIs in Africa (ICASA), treatment advocates and activists from all over Africa united to urge ViiV Healthcare to allow affordable access to

10 July 2014

The first Middle East and North Africa Community Advisory Board (MENA-CAB)

Advocacy, AIDS, Algeria, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Intellectual Proprety, Libya, Middle East, Morocco, North Africa, REGION, Tunisia 82 Views

Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the